During the 20th annual North American Cystic Fibrosis Conference (NACFC) in Denver, Pamela Davis, M.D., Ph.D, Case School of Medicine Interim Dean, received the Paul di Sant'Agnese Award. The award is the Cystic Fibrosis Foundation's highest honor for scientific research achievement and is given annually to the scientist who made the most significant strides in CF studies.
"While making pioneering discoveries in CF and leading one of the most innovative translation centers for developing new therapies, Dr. Davis has remained a well-respected and beloved caregiver to CF patients in Cleveland," said CF Foundation President and CEO Robert J. Beall, Ph.D. "It was an honor to present the Paul di Sant'Agnese Award to Dr. Davis."
The award has personal meaning for Dr. Davis, who mentored under Dr. di Sant'Agnese while working at the National Institutes of Health. "Dr. di Sant'Agnese has been such an inspiration not only to me but many physicians who also believed in the reward of academic medicine and world-changing medical research," said Davis.
One of her first novel and important contributions to CF research was a new approach for treating lung disease by limiting the excessive inflammatory response. In a four-year, double-blind, placebo-controlled trial, Davis showed that high dose ibuprofen dramatically slows down progression of CF lung disease. This remains the only treatment directly demonstrated to alter disease progression.
In addition, Dr. Davis has published more than 120 original articles, holds seven U.S. patents, is a founding scientist of Copernicus Therapeutics Inc. and serves on many medical, academic, research-based and cystic fibrosis-specific boards. Davis also directs a State of Ohio Biomedical Research and Technology Transfer Center on Targeted Nanoparticles for Imaging and Therapeutics.
Davis has been a recipient of the Rosenthal Prize for Academic Pediatrics, the Smith College Medal, an inductee of the Cleveland Medical Hall of Fame and named regularly in "Best Doctors in America" and "Top Doctors."
"I believe a cure for cystic fibrosis will be found in my lifetime," said Dr. Davis. "I hope to be a part of that triumph."
Founded in 1843, the Case Western Reserve University School of Medicine is the largest medical research institution in Ohio and 12th largest among the nation's medical schools for research funding from the National Institutes of Health. Eleven Nobel Laureates have been affiliated with the school.
The School of Medicine is recognized throughout the international medical community for outstanding achievements in teaching. In 2002, it became only the third medical school in history to receive the best review possible from the national body responsible for accrediting the nation's medical schools. It ranks in the top 25 among U.S. research-oriented medical schools in the U.S. News and World Report Guide to Graduate Education. Annually, the School of Medicine trains more than 600 M.D. and M.D./Ph.D. students. The School's Western Reserve2 curriculum interweaves four themes--research and scholarship, clinical mastery, leadership, and civic professionalism--to prepare students for the practice of evidence-based medicine in the rapidly changing health care environment of the 21st century.
The School of Medicine's primary clinical affiliate is University Hospitals at Case Medical Center and the school is additionally affiliated with MetroHealth Medical Center, the Louis Stokes Cleveland Department of Veterans Affairs Medical Center, and the Cleveland Clinic Foundation, with which it opened the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in 2004.
The Cystic Fibrosis Foundation is the leading organization in the United States devoted to cystic fibrosis, a life-threatening genetic disease that affects about 30,000 people nationwide. The CF Foundation has more than 80 chapters and fund-raising offices nationwide and supports a network of more than 115 Foundation-accredited CF care centers, which provide patients and families with vital treatment and other CF resources.
Based in Bethesda, Md., the CF Foundation is one of the most efficient organizations of its kind. In 2005, nearly 90 percent of every dollar of revenue raised was available for investment in CF research, care and education programs. The National Institutes of Health and many prominent publications, including Forbes and USA Today, have heralded the Foundation's innovative business model, which fuels drug discovery and development programs. For more information, visit http://www.cff.org.
Case Western Reserve University is committed to the free exchange of ideas, reasoned debate and intellectual dialogue. Speakers and scholars with a diversity of opinions and perspectives are invited to the campus to provide the community with important points of view, some of which may be deemed controversial. The views and opinions of those invited to speak on the campus do not necessarily reflect the views of the university administration or any other segment of the university community.